Proceedings of the 2023 annual meeting of European Association for the Study of Diabetes: Advances in diabetes mellitus and other metabolic diseases
10.3760/cma.j.cn311282-20231213-00211
- VernacularTitle:2023年欧洲糖尿病研究学会年会会议纪要：糖尿病与其他代谢性疾病的学术进展
- Author:
Fei SUN
1
;
Bin GAO
Author Information
1. 空军军医大学第二附属医院内分泌科，西安 710038
- Keywords:
Diabetes mellitus;
Complications/Comorbidities;
Metabolic Diseases;
Obesity;
European Association for the Study of Diabetes
- From:
Chinese Journal of Endocrinology and Metabolism
2024;40(3):258-266
- CountryChina
- Language:Chinese
-
Abstract:
The 59th European Association for the Study of Diabetes(EASD) annual meeting was held in Hamburg, Germany from October 2nd to 6th, 2023. In the past decades, there have been significant advancements in the clinical management of diabetes. Novel anti-hyperglycemic medications, particularly those targeting the glucagon-like peptide-1 receptor and dual/multiple receptors, have garnered attention. These medications show great promise in glycemic control, weight reduction, metabolic improvements, and additional benefits. This article provided an overview of some of the key topics discussed at this EASD conference.
